Alere San Diego, Inc. Watch

from S-4 8 pages Sixteenth Supplemental Indenture

from S-4/A 9 pages Eleventh Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 19, 2010, Among New Binax, Inc., New Biosite Incorporated, Alere Newco, Inc., and Alere Newco II, Inc. ( the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 9 pages Tenth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 19, 2010, Among New Binax, Inc., New Biosite Incorporated, Alere Newco, Inc., and Alere Newco II, Inc. (The “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 8 pages Ninth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 1, 2010, Among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc., and Scientific Testing Laboratories, Inc. ( the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 8 pages Eighth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 1, 2010, Among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc., and Scientific Testing Laboratories, Inc. (The “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Seventh Supplemental Indenture (This “Supplemental Indenture”), Dated as of January 29, 2010, Among Rmd Networks, Inc. ( the “New Guarantor”), Subsidiary of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Sixth Supplemental Indenture (This “Supplemental Indenture”), Dated as of January 29, 2010, Among Rmd Networks, Inc. (The “New Guarantor”), a Subsidiary of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Fifth Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 25, 2009, Among Free & Clear, Inc. and Tapesty Medical, Inc. (Collectively, the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Fourth Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 25, 2009, Among Free & Clear, Inc. and Tapestry Medical, Inc. (Collectively, the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-3ASR 57 pages Inverness Medical Innovations, Inc., as Issuer, and , as Trustee Indenture Dated as of , 20

from 10-Q 3 pages [Face of Certificate] [Logo] Number Bst Shares Incorporated Under the Laws of the State of Delaware This Certificate Is Transferable in the City of Boston, Ma or New York, Ny See Reverse for Certain Definitions and a Statement as to Rights, Preferences, Privileges and Restrictions, if Any Cusip 090945 10 6 Fully Paid and Nonassessable Shares of Common Stock, $.01 Par Value Per Share, of Biosite Incorporated Vice President, Finance and Chief Financial Officer President and Chief Executive Officer Countersigned and Registered: American Stock Transfer & Trust Company Transfer Agent and Registrar by Authorized Signature [Back of Certificate]

from 8-A12G/A ~5 pages Amendment No. 2 to Rights Agreement

from 8-A12G/A ~1 page Amendment No. 1 to Rights Agreement

from 8-A12G ~50 pages Indenture or similar

from S-1/A 1 page Indenture or similar